Document Detail

Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II).
MedLine Citation:
PMID:  17297027     Owner:  NLM     Status:  MEDLINE    
The fixed dose combination of atovaquone and proguanil hydrochloride, marketed under the trade name Malarone, is the most recently approved agent in North America for the prevention and treatment of chloroquine- and multi-drug resistant Plasmodium falciparum malaria. In both adult and pediatric populations, atovaquone-proguanil demonstrates consistently high protective efficacy against P. falciparum, and in treatment trials, cure rates exceed 93%. Only a handful of genetically confirmed treatment failures have been reported to date. Atovaquone-proguanil has an excellent safety profile during both prophylaxis and treatment courses, with severe adverse events rarely reported. This topical review will examine the evidence behind the current indications for use of atovaquone-proguanil, and will summarize the current body of literature surrounding safety and tolerability.
Andrea K Boggild; Monica E Parise; Linda S Lewis; Kevin C Kain
Related Documents :
15843787 - Congenital malaria--nassau county, new york, 2004.
11904097 - Nonoperative treatment of splenic rupture in malaria tropica: review of literature and ...
17694777 - Bilateral pneumoblepharon/palpebral emphysema in nigeria--a case report.
9178597 - Vulvovaginal tuberculosis: a case report.
23838487 - Carotid sheath lipoma: first case report in the english literature.
22294057 - Minimally invasive intrathoracic anastomosis after ivor lewis esophagectomy for cancer:...
Publication Detail:
Type:  Congresses    
Journal Detail:
Title:  The American journal of tropical medicine and hygiene     Volume:  76     ISSN:  0002-9637     ISO Abbreviation:  Am. J. Trop. Med. Hyg.     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-02-13     Completed Date:  2007-04-03     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0370507     Medline TA:  Am J Trop Med Hyg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  208-23     Citation Subset:  AIM; IM    
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antimalarials / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Atovaquone / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Chloroguanide / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Drug Combinations
Malaria, Falciparum / drug therapy,  parasitology,  prevention & control*
Plasmodium falciparum / growth & development*
Randomized Controlled Trials as Topic
Reg. No./Substance:
0/Antimalarials; 0/Drug Combinations; 0/malarone; 500-92-5/Chloroguanide; 94015-53-9/Atovaquone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse thera...
Next Document:  Mefloquine treatment for uncomplicated falciparum malaria in young children 6-24 months of age in no...